ES2953855T3 - Detección de proteínas mal plegadas - Google Patents

Detección de proteínas mal plegadas Download PDF

Info

Publication number
ES2953855T3
ES2953855T3 ES15839278T ES15839278T ES2953855T3 ES 2953855 T3 ES2953855 T3 ES 2953855T3 ES 15839278 T ES15839278 T ES 15839278T ES 15839278 T ES15839278 T ES 15839278T ES 2953855 T3 ES2953855 T3 ES 2953855T3
Authority
ES
Spain
Prior art keywords
protein
misfolded
soluble
sample
incubation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15839278T
Other languages
English (en)
Spanish (es)
Inventor
Claudio Soto Jara
Mohammad Shahnawaz
Russell M Lebovitz
Benedikt K Vollrath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Amprion Inc
Original Assignee
University of Texas System
University of Texas at Austin
Amprion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin, Amprion Inc filed Critical University of Texas System
Application granted granted Critical
Publication of ES2953855T3 publication Critical patent/ES2953855T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
ES15839278T 2014-09-11 2015-09-11 Detección de proteínas mal plegadas Active ES2953855T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462049306P 2014-09-11 2014-09-11
PCT/US2015/049844 WO2016040907A1 (en) 2014-09-11 2015-09-11 Detection of misfolded proteins

Publications (1)

Publication Number Publication Date
ES2953855T3 true ES2953855T3 (es) 2023-11-16

Family

ID=55454515

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15839278T Active ES2953855T3 (es) 2014-09-11 2015-09-11 Detección de proteínas mal plegadas

Country Status (15)

Country Link
US (1) US20160077112A1 (enExample)
EP (2) EP3191599B1 (enExample)
JP (2) JP6980953B2 (enExample)
KR (1) KR102448128B1 (enExample)
CN (1) CN107208125A (enExample)
AU (1) AU2015314783B2 (enExample)
BR (1) BR112017004899A2 (enExample)
CA (1) CA2960830C (enExample)
ES (1) ES2953855T3 (enExample)
HR (1) HRP20231232T1 (enExample)
IL (2) IL251052B (enExample)
MX (1) MX2017003269A (enExample)
PL (1) PL3191599T3 (enExample)
SG (2) SG10202008464UA (enExample)
WO (1) WO2016040907A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10989718B2 (en) 2014-09-11 2021-04-27 Amprion, Inc. Detection of misfolded alpha synuclein protein
US11079396B2 (en) * 2019-09-04 2021-08-03 Amprion, Inc. Alpha-synuclein detection using beads
GB201611840D0 (en) 2016-07-07 2016-08-24 Univ Court Of The Univ Of Edinburgh The Alpha-synuclein detection assay
BR112019016374A2 (pt) 2017-02-17 2020-04-07 Bristol-Myers Squibb Company anticorpos para alfa-sinucleína e usos dos mesmos
CN110869763B (zh) 2017-05-16 2022-07-29 安培里翁公司 错误折叠tau蛋白质的检测
CA3074914A1 (en) 2017-10-02 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Assay for the detection of alpha-synuclein seeding activity associated with synucleinopathies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
US20200309796A1 (en) * 2017-12-21 2020-10-01 H. Lundbeck A/S Assay, method and treatment of alpha-synucleinopathies
CN108088816A (zh) * 2018-01-23 2018-05-29 深圳市国赛生物技术有限公司 小型特定蛋白分析仪
GB201803553D0 (en) 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
US20190353669A1 (en) * 2018-05-16 2019-11-21 Amprion, Inc. Detection of Brain Injury or Neurological Disease using Tau Protein
US12437843B2 (en) * 2018-09-21 2025-10-07 Gdm Holding Llc Predicting protein structures using geometry neural networks that estimate similarity between predicted protein structures and actual protein structures
JP7376040B2 (ja) * 2019-09-03 2023-11-08 国立大学法人京都工芸繊維大学 神経変性疾患におけるバイオマーカー分子の検出方法
KR102277871B1 (ko) * 2019-12-17 2021-07-15 원광대학교산학협력단 소변의 알파-씨누클레인 중합체 측정에 의한 파킨슨병 진단 정보의 수집방법 및 그 키트
WO2021198098A1 (en) 2020-04-03 2021-10-07 Universität Zürich Improved method of detecting biomarkers in a biological sample
MX2022014319A (es) * 2020-05-18 2023-02-27 Amprion Inc Sustratos de alfa-sinucleína y métodos para la fabricación y el uso de los mismos.
WO2022105923A1 (zh) * 2020-11-21 2022-05-27 浙江数问生物技术有限公司 用于检测生物样本中的错误折叠蛋白质的装置和方法
US20240192230A1 (en) * 2021-04-15 2024-06-13 The Brigham And Women’S Hospital, Inc. Digital Protein Misfolding Assays
CN114199875B (zh) * 2022-02-18 2022-05-20 之江实验室 一种蛋白质多聚体是否可作为力缓冲剂的判断方法及装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1712920T3 (da) 2000-07-07 2009-05-11 Merck Serono Sa Tidlig diagnose af konformationelle sygdomme
US20030027210A1 (en) * 2001-01-03 2003-02-06 Daniel Benjamin Alpha synuclein aggregation assays
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
EP1820806A1 (en) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
ATE528649T1 (de) * 2005-02-15 2011-10-15 Adlyfe Inc Verfahren zum nachweis falsch gefalteter proteine und prionen
JP2009537153A (ja) * 2006-05-19 2009-10-29 アルニラム ファーマシューティカルズ， インコーポレイテッド ＡｈａのＲＮＡｉ調節およびその治療上の使用
WO2008030973A2 (en) * 2006-09-06 2008-03-13 The Board Of Regents Of The University Of Texas System Methods and compositions for the detection of protein folding disorders
JP2010043865A (ja) * 2006-12-12 2010-02-25 Olympus Corp 異常型プリオンの検出方法
CN102666577A (zh) * 2009-11-24 2012-09-12 前体生物药物股份公司 诊断阿尔茨海默病或轻度认知损害的新的诊断方法
US9133343B2 (en) * 2009-11-30 2015-09-15 Enzo Biochem, Inc. Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications
WO2012099884A1 (en) * 2011-01-18 2012-07-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for amplification and detection of prions
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
WO2016040903A1 (en) * 2014-09-11 2016-03-17 Board Of Regents Of The University Of Texas System Detection of misfolded amyloid beta protein

Also Published As

Publication number Publication date
JP7104943B2 (ja) 2022-07-22
AU2015314783A1 (en) 2017-04-27
BR112017004899A2 (pt) 2017-12-12
EP4292654A3 (en) 2024-01-03
KR102448128B1 (ko) 2022-09-27
EP4292654A2 (en) 2023-12-20
IL291809A (en) 2022-06-01
IL251052B (en) 2022-05-01
HRP20231232T1 (hr) 2024-01-19
CA2960830A1 (en) 2016-03-17
JP6980953B2 (ja) 2021-12-15
CN107208125A (zh) 2017-09-26
KR20170103741A (ko) 2017-09-13
US20160077112A1 (en) 2016-03-17
MX2017003269A (es) 2017-12-04
IL251052A0 (en) 2017-04-30
EP3191599B1 (en) 2023-08-02
PL3191599T3 (pl) 2023-12-27
EP3191599A1 (en) 2017-07-19
EP3191599C0 (en) 2023-08-02
AU2015314783B2 (en) 2021-10-21
SG10202008464UA (en) 2020-10-29
JP2017530373A (ja) 2017-10-12
EP3191599A4 (en) 2018-03-14
CA2960830C (en) 2023-09-05
IL291809B2 (en) 2023-06-01
SG11201701953RA (en) 2017-04-27
WO2016040907A1 (en) 2016-03-17
JP2022000629A (ja) 2022-01-04

Similar Documents

Publication Publication Date Title
ES2953855T3 (es) Detección de proteínas mal plegadas
US12540949B2 (en) Detection of misfolded alpha synuclein protein
US9910049B2 (en) Detection of misfolded amyloid beta protein
US20220137073A1 (en) Detection of misfolded tau protein
US20210102961A1 (en) Detection of misfolded proteins
HK40105178A (en) Detection of misfolded proteins
US20190137515A1 (en) Methods for estimating misfolded protein concentration in fluids and tissue by quantitative pmca
US20190353669A1 (en) Detection of Brain Injury or Neurological Disease using Tau Protein